Literature DB >> 33223038

The therapeutic and neuroprotective effects of an antiepileptic drug valproic acid in glioma patients.

Cong Li1, Huijing Chen2, Qijia Tan1, Caijun Xie1, Wengang Zhan1, Aruna Sharma3, Hari Shanker Sharma4, Zhiqiang Zhang5.   

Abstract

Glioma is the most common primary malignant brain tumor in adults and the patients have poor prognosis despite treatment with surgery, radiotherapy and chemotherapy. The anti-epileptic drug, valproic acid (VPA) as a HDAC inhibitors is often used in glioma patients even if the patients don't have brain tumors associated epilepsy (BAE). Some previous studies have found that VPA not only has anti-epileptic effect, but also has anti-glioma growth effect through enhance radiotherapy sensitivity or other mechanism. Then VPA is reported to improve the survival of glioma patients receiving chemoradiation therapy. In addition, there are limited researches have shown that VPA has a neuroprotective effect in protect normal cells and tissues from the deleterious effects of treatment of glioma, especially radiotherapy. We'll give a brief overview of these effects of VPA in glioma patients.
© 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Glioma; Neuroprotective effect; Valproic acid

Mesh:

Substances:

Year:  2020        PMID: 33223038     DOI: 10.1016/bs.pbr.2020.09.008

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  2 in total

1.  Different Effects of Valproic Acid on SLC12A2, SLC12A5 and SLC5A8 Gene Expression in Pediatric Glioblastoma Cells as an Approach to Personalised Therapy.

Authors:  Eligija Damanskienė; Ingrida Balnytė; Angelija Valančiūtė; Marta Marija Alonso; Donatas Stakišaitis
Journal:  Biomedicines       Date:  2022-04-22

2.  Valproic Acid-Like Compounds Enhance and Prolong the Radiotherapy Effect on Breast Cancer by Activating and Maintaining Anti-Tumor Immune Function.

Authors:  Zuchao Cai; David Lim; Guochao Liu; Chen Chen; Liya Jin; Wenhua Duan; Chenxia Ding; Qingjie Sun; Junxuan Peng; Chao Dong; Fengmei Zhang; Zhihui Feng
Journal:  Front Immunol       Date:  2021-05-12       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.